Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial - Motzer, Robert J; Escudier, Bernard; McDermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthélémy, Philippe; Hammers, Hans J; George, Saby; Grünwald, Viktor; et al. (Journal for immunotherapy of cancer, 2020)
Keywords: Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer; Cancer therapies; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - pathology; Cell death; clinical trials, phase III as topic; Clinical/Translational Cancer Immunotherapy; CTLA-4 antigen; Female; Follow-Up Studies; Humans; Immunotherapy; Inhibitor drugs; Ipilimumab - pharmacology; Ipilimumab - therapeutic use; Kidney cancer; kidney neoplasms; Kidney Neoplasms - drug therapy; Kidney Neoplasms - mortality; Kidney Neoplasms - pathology; Male; Monoclonal antibodies; Nivolumab - pharmacology; Nivolumab - therapeutic use; Patients; Population; programmed cell death 1 receptor; Quality of life; Sunitinib - pharmacology; Sunitinib - therapeutic use; Survival Analysis; Targeted cancer therapy; clinical trials, phase III as topic; programmed cell death 1 receptor; CTLA-4 antigen; kidney neoplasms; immunotherapy